Preliminary studies on the molecular events leading to tumorigenesis in ACC [7] led to the first molecular targeted therapies, such as IGF1R (insulin-like growth factor 1 receptor) [8] and VEGF (vascular endothelial growth factor) [9] inhibitors, which all proved disappointing [10]. The gene discussed is VEGFA; the disease is adrenal cortex carcinoma.